Highbridge, Athyrium Provide New $72.5MM Novelion Therapeutics Facility
Certain funds managed by Athyrium Capital Management and Highbridge Capital Management provided a facility consisting of $50 million in new secured first lien term loans and $22.5 million of new secured term loans to Novelion Therapeutics, a biopharmaceutical company.
November 12, 2018
Athyrium Capital Management | Highbridge Capital | Novelion Therapeutics
Rita Garwood